ArticleScience translational medicine2021
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 2 pooled it
14.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 2 syntheses or guidelines pooled it, 218 citations in OpenAlex.
- Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Frontiers in immunology · 2024Pooled it
- PEGylated IL2 and tumor-targeted radiotherapy augment CD8Theranostics · 2026Trial
- Tumor cell membrane‑coated MOF‑199 nanoparticles co‑loaded with auranofin and celecoxib enhance single‑dose radiotherapy and anti‑PD‑L1 therapy in cervical cancer.Journal of nanobiotechnology · 2026Article
- Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma.bioRxiv : the preprint server for biology · 2026Article
- Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent.Science advances · 2026Article
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models.Cancer immunology research · 2026Article
- Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Efficacy and safety of radiotherapy following chemoimmunotherapy in extensive-stage small cell lung cancer: a retrospective comparative cohort study of consolidation versus salvage indications.Journal of thoracic disease · 2026Article
- Novel Radiotherapy Delivery Modalities and Their Potential to Synergize with Immunotherapy.Biomedicines · 2026Article
- Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis.Discover oncology · 2026Article
- CD8 immunoPET imaging to stratify response and guide combination immunotherapy and radiation in triple negative breast cancer.Breast cancer research : BCR · 2026Article
- Neoadjuvant Therapy-Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis.Cancer science · 2026Article
- Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS-STING pathway: mechanisms, challenges, and combination therapy strategies.Molecular cancer · 2026Review
- Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy.Journal for immunotherapy of cancer · 2026Article
- Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases.Precision oncology · 2026Article
- Tumour Microenvironment-Informed Radiotheranostics: Why and How Nuclear Medicine Could Advance Precision Oncology in the Decade Ahead.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026Article
- CD4Journal for immunotherapy of cancer · 2026Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Ravi B PatelDepartment of Radiation Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA 15213, USA. patelr20@upmc.edu zmorris@humonc.wisc.edu.ORCID 0000-0002-8328-746X
Reinier HernandezDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-0729-2179
Peter CarlsonDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0003-1908-7233
Joseph GrudzinskiDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.
Amber M BatesDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-5184-4532
Justin C JagodinskyDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-6204-4899
Amy ErbeDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.
Ian R MarshDepartment of Medical Physics, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-0031-9746
Ian ArthurDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-3927-3570
Eduardo Aluicio-SarduyDepartment of Medical Physics, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-7889-9162
Raghava N SriramaneniDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-9452-8708
Won Jong JinDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0003-4147-9735
Christopher MasseyDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.
Alexander L RakhmilevichDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.
David VailDepartment of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-1964-3693
Johnathan W EngleDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-3399-7228
Trang LeDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53792, USA.
KyungMann KimDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53792, USA.
Bryan BednarzDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-7467-9816
Paul M SondelDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.
Jamey WeichertDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-2048-6381
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA. patelr20@upmc.edu zmorris@humonc.wisc.edu.ORCID 0000-0001-5558-3547
University of Wisconsin–Madison · USUPMC Hillman Cancer Center · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MUW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MUnderstanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MRadionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2020 to 2024
$12.5MU.W. RADIOLOGICAL SCIENCES TRAINING PROGRAMT32CA009206 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Bryan Patrick Bednarz · 1985 to 2026
$12.1MProject 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8MINTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3MNRSA Training CoreTL1TR002375 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Vivek Prabhakaran · 2017 to 2026
$8.4MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MWaisman Intellectual and Developmental Disabilities Research Center Down Syndrome RegistryU54HD090256 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI MESSING, ALBEE · 2016 to 2020
$6.0MImmunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0MCombining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9MNCATS NIH HHS TL1 TR002375NCI NIH HHS F30 CA250263NCI NIH HHS K08 CA241319NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS P30 CA047904NCI NIH HHS R35 CA197078NCI NIH HHS T32 CA009206NCI NIH HHS U01 CA233102NCI NIH HHS U54 CA232568NICHD NIH HHS U54 HD090256NIDCR NIH HHS P50 DE026787NIGMS NIH HHS T32 GM008692NIH HHS DP5 OD024576
Abstract
Molecular and cellular effects of radiotherapy on tumor microenvironment (TME) can help prime and propagate antitumor immunity. We hypothesized that delivering radiation to all tumor sites could augment response to immunotherapies. We tested an approach to enhance response to immune checkpoint inhibitors (ICIs) by using targeted radionuclide therapy (TRT) to deliver radiation semiselectively to tumors. NM600, an alkylphosphocholine analog that preferentially accumulates in most tumor types, chelates a radioisotope and semiselectively delivers it to the TME for therapeutic or diagnostic applications. Using serial
Indexed as
CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsAnimalsCell Line, TumorDogsImmunotherapyMiceRadioisotopesTumor Protein, Translationally-Controlled 1Immune Checkpoint InhibitorsRadioisotopesTpt1 protein, mouseTumor Protein, Translationally-Controlled 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.